Lecanemab’s Positive Clinical Trial Results Give Alzheimer’s Patients Hope

Drug demonstrates significant reduction in the progression of Alzheimer’s

Washington, DC (September 27, 2022) – Alzheimer’s patients and their loved ones have new reason for hope following Phase 3 trial results of lecanemab released by Eisai Tuesday night. The results showed the drug reduced the progression of Alzheimer’s by 27 percent over 18 months, compared to placebo. Like other drugs in the same class, lecanemab is designed to slow the progression of Alzheimer’s disease by targeting amyloid plaque buildup in the brain. UsAgainstAlzheimer’s chair and co-founder George Vradenburg issued the following statement in response to Eisai’s announcement:

“This is very important and quite positive news that gives our nation’s 6 million Alzheimer’s patients and their loved ones reason to hope again. In fact, the data is a reminder that each drug in this class of therapies is quite different."

“Patients can’t wait for treatment. We hope the Food and Drug Administration’s (FDA) approval process is quick and that, once approved, CMS will do the right thing and cover it.”

# # #

About UsAgainstAlzheimer’s

UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. We take on the toughest problems; bring all of “Us” together to break down barriers; advocate for research that will speed treatments to market; and drive changes that matter most to people living with the disease. We will not rest until brain-span equals lifespan - for everyone.